

# PRELIMINARY SCIENTIFIC PROGRAMME



## WEDNESDAY NOVEMBER 20, 2019

WEDNESDAY NOVEMBER 20, 2019		
08:00-08:30	REGISTRATION	
	ROOM A	ROOM B
08:30-16.30	<b>Pre-Course I</b> Surgical course – live videos in Minimally Invasive Esophagectomy	<b>Pre-Course II</b> Endoscopy-hands on
18.00-19.30	HALL A <b>OPENING CEREMONY</b> Chairs: <i>T. Liakakos, M. Nilsson</i> <ul style="list-style-type: none"> <li>➤ Opening remarks from the ESDE President <i>M. Nilsson</i></li> <li>➤ Welcome from the 2019 ESDE Athens Congress President <i>T. Liakakos</i></li> <li>➤ Lecture “Medicine &amp; Surgery in Ancient Greece” <i>S. Geroulanos</i></li> </ul>	
19.30	SKALKOTAS FOYER  <b>WELCOME RECEPTION</b>	

08:00-10:30

REGISTRATION

HALL A

HALL B

08:30-10:00

**Staging in esophageal cancer: Where are we heading**

Chairs: **T. Liakakos, J. van Lanschot**

- TNM 8<sup>th</sup> edition: What's new and what are the clinical implications?  
**P. Nafteux**
- Clinical staging: Pitfalls, limitations and where do we go from here?  
**D. Low**
- Staging by novel molecular subtypes with genome and transcription analysis  
**D. Roukos**
- Important aspects of preoperative endoscopic evaluation of esophageal cancer  
**M. van Berge Henegouwen**
- Esophageal cancer clinical restaging after neoadjuvant therapy in 2019: State-of-the-art  
**M. Nilsson**

**Oral Presentations and Discussion**

Chairs: **A. Kechagias, D. Schizas**

1. Giant esophageal polyp protruding through the mouth: a rare case  
**K. Dinaki**
2. Esophageal motility of lung transplant recipients diagnosed with systemic connective tissue disorder: a single-center experience  
**M. Csucska**
3. A propensity score-matched case-control study to compare POEM and laparoscopic Heller myotomy in the treatment of esophageal achalasia  
**A. Costantini**
4. Quality of life for achalasia patients is the same after per-oral endoscopic myotomy (POEM) and Heller myotomy  
**G.Z. poulou**
5. The association of perioperative quality-of-care parameters (textbook outcome) with long term outcome after esophagectomy for esophageal cancer  
**MC Kalf**
6. A chemoradiotherapy treatment response mRNA signature as predictor for esophageal adenocarcinoma treated according to the CROSS regimen  
**K.K. Krishnadath**
7. Lasting symptoms after esophageal resection (LASER) – European multi-center cross-sectional study  
**S. Markar**
8. Minimally invasive oesophagectomy: a long learning curve for better oncological resection and improved survival outcome  
**F. Di Maggio**

		<p>9. Anastomotic techniques and associated morbidity in total minimally-invasive transthoracic esophagectomy – results from the esobenchmark database <b>W. Schroeder</b></p> <p>10. 10-year follow-up of a randomised controlled trial comparing neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS) <b>B.M. Eyck</b></p>
10:00-10:30	<b>Coffee break</b>	
10:30-12:00	<p><b>Hot topics</b> Chairs: <b>M. Cuesta, R. Rosati</b></p> <ul style="list-style-type: none"> <li>• Is esophageal cancer the next malignancy that should be considered for screening: what is the evidence <b>P. Siersema</b></li> <li>• Endoscopic management of Barrett's esophagus in the days of quality assessment <b>I. Papanikolaou</b></li> <li>• Robotic esophageal surgery: State-of-the-art <b>R. van Hillegersberg</b></li> <li>• Results from the International Oesophago-Gastric Anastomosis Audit (OGAA) <b>E. Griffiths</b></li> <li>• Immunotherapy: a panacea for the future? <b>A. Chaudry</b></li> </ul>	<p><b>Barrett's esophagus</b> Chairs: <b>G. Karamanolis, R. Tutuian</b></p> <ul style="list-style-type: none"> <li>• Definition, classification and surveillance of Barrett's esophagus <b>R. Penagini</b></li> <li>• Molecular markers for progression to dysplasia and adenocarcinoma <b>M. Gazouli</b></li> <li>• Endoscopic treatment <b>S. Michopoulos</b></li> <li>• Optimal prevention of progression from GERD to cancer <ul style="list-style-type: none"> <li>➤ The gastroenterologist's view <b>J. Vlahogiannakos</b></li> <li>➤ The surgeon's view <b>D. Theodorou</b></li> </ul> </li> </ul>
12:00-13:00	<p><b>PLENARY SESSION – The “Christophe Mariette” Lecture</b> Chairs: <b>T. Lerut, M. Nilsson</b></p> <p>Multimodality Treatment in esophageal cancer <b>J. Reynolds</b></p>	<b>Plenary Session in HALL A</b>
13:00-14:00	<b>Lunch break</b>	
14:00-15:30	<p><b>Oral presentations and discussion</b> Chairs: <b>P. Grimminger, I. Rouvelas</b></p> <p>1. Direct oral feeding following minimally invasive esophagectomy (NUTRIENT II trial): an international, multicenter, open-label randomized controlled trial. <b>L. F.C. Fransen</b></p>	<p><b>GERD – Refractory GERD</b> Chairs: <b>P. Siersema, D. Titcomb</b></p> <ul style="list-style-type: none"> <li>• State-of-the-art: Diagnostic methods in GERD <b>E. Savarino</b></li> </ul>

2. Treatment of anastomotic leakage after esophagectomy (TENTACLE study)

**M. Verstegen**

3. Outcomes of Ivor Lewis versus McKeown oesophagectomy for cancer: a propensity score matched analysis of the Netherlands Cancer Registry

**M. Verstegen**

4. Non-radical esophagectomy for esophageal cancer; a nationwide study on incidence, risk factors and outcomes in Sweden

**D. Edholm**

5. Surveillance using FDG-uptake in the primary tumour on PET/CT in patients with oesophageal cancer and a clinically complete response after neoadjuvant chemoradiotherapy

**M.J. Valkema**

6. Tumor volume regression during neoadjuvant chemoradiotherapy for esophageal cancer: a prospective study with weekly MRI

**I. L. Defize**

7. Interval distant metastases during or after neoadjuvant chemoradiotherapy for esophageal or gastroesophageal junction cancer: a Nation-wide population-based cohort study

**T.E. Kroese**

8. TGF-beta1 and TGF-beta2 mediated epithelial-mesenchymal transition in esophageal adenocarcinoma cells

**R. Thieme**

9. E-cadherin expression correlates with progression of esophageal squamous cell carcinoma

**H. Koda**

10. Malnutrition indices as prognostic factors for postoperative complications in esophageal cancer patients

**I. Lidoriki**

- Refractory GERD: Subtypes, pathophysiology and therapy

**R. Tutuian**

- More than thirty years experience with the use of proton pump inhibitors

**A. Manolakis**

- Endoscopic management. Indications and limitations

**A. Kofokotsios**

- The optimal surgical procedure for reflux disease. When and how?

**L. Lundell**

16:00-17:30

## **Optimizing outcomes in multimodality treatment of esophageal cancer**

Chairs: **L. Bonavina, D. van der Peet**

- Prehabilitation in esophageal cancer surgery  
**K. Moorthy**
- Neoadjuvant and perioperative therapy in current clinical practice  
**M. Nilsson**
- From CROSS to SANO trial. Is surgery always needed?  
**J. van Lanschoot**
- When and why the FLOT-4 regimen?  
**D. Ziogas**
- 3-years results of the French MIRO trial  
**G. Piessen**

## **Oral presentations and discussion**

Chairs: **M. van Berge Henegouwen, O. Lyros**

1. Diaphragmatic hernia after Ivor-Lewis oesophagectomy: analysis of risk factors and surgical repair results  
**P. Parise**
2. Meta-analysis of prognostic factors for overall survival in patients undergoing oesophagectomy for oesophageal cancers  
**E.J. Marson**
3. Microanatomy based standardization of left upper mediastinal lymph node dissection in thoracoscopic esophagectomy in the prone position  
**Y. Shirakawa**
4. Gastric conduit necrosis after esophagectomy: risk prediction, management and outcomes  
**A. van der Veen**
5. Adjuvant chemoradiotherapy is beneficial in margin positive patients following neo-adjuvant chemotherapy and surgery for lower oesophageal and GOJ adenocarcinoma  
**R. Boff**
6. Worldwide Techniques and Outcomes of Robot-assisted Minimally Invasive Esophagectomy (RAMIE): Results from the International UGIRA Registry  
**B. F. Kingma**
7. Finding factors associated with safe implementation of Ivor Lewis totally minimally esophagectomy  
**L. Claassen**
8. Calcification in the descending aorta predicts postoperative leakage of intra-thoracic anastomosis after esophagectomy for cancer  
**A. Kechagias**
9. Serum C-reactive protein can be an early predictor of length of stay after minimally invasive oesophagectomy  
**G. Corsi**
10. Short-term results of a randomized controlled trial of standard vs. prolonged time to surgery after neoadjuvant chemoradiation for

		cancer <b>K. Nilsson</b>
		<b>17:45-18:45 ESDE Business Meeting</b>
19:00	<b>Visit to Acropolis Museum &amp; Congress Dinner (optional)</b>	

**FRIDAY NOVEMBER 22, 2019**

08:00-10:30	REGISTRATION	
	HALL A	HALL B
08:30-10:00	<p><b><i>Surgical strategies for esophageal cancer</i></b>  <i>Chairs: A. Chaudry, P. Nafteux</i></p> <ul style="list-style-type: none"> <li>• Overview of types of open and minimal invasive resections  <b>R. Rosati</b></li> <li>• Positioning and extent of resection in MIE. The upper paratracheal nodal dissection challenge  <b>L. Bonavina</b></li> <li>• MIE. The difficult intrathoracic anastomosis  <b>A. Charalabopoulos</b></li> <li>• New robotics and artificial intelligence in esophageal cancer surgery  <b>P. Grimminger</b></li> </ul>	<p><b><i>Oral Presentations and Discussion</i></b>  <i>Chairs: I. Karavokyros, A. Kechagias</i></p> <ol style="list-style-type: none"> <li>1. Lyon consensus criteria significantly changes the PH impedance diagnosis of gastroesophageal reflux disease (GERD)  <b>A. Ioannou</b></li> <li>2. A slightly crazy but informative experiment of the effect of the head down posture on the characteristics of oesophageal motility and oesophagogastric junction using High resolution oesophageal manometry  <b>B. Nagammapur</b></li> <li>3. Computed Tomography can predict outcomes after caustic injury ingestion?  <b>J. Weindelmayer</b></li> <li>4. Twenty-five years of laparoscopic treatment for esophageal achalasia: our experience on 1001 laparoscopic Heller-Dor operations  <b>R. Salvador</b></li> <li>5. Genomic biomarkers for cancer risk in Barrett's esophagus: an update on the longitudinal Dutch Barrett's esophagus cohort  <b>K. K. Krishnadath</b></li> <li>6. Classification of Barrett's carcinoma specimens by hyperspectral imaging (HSI)  <b>R. Thieme</b></li> <li>7. Very long-term (5-19 years) follow-up paraesophageal hernia repair: permanent mesh vs standard cruroplasty  <b>M. Pamela</b></li> <li>8. The epidemiology of anti-reflux surgery in Denmark 2000-2017: a nationwide registry-based population study  <b>J.S. Ljungdahl</b></li> <li>9. Role of malnutrition in oesophageal surgery for cancer  <b>R. Alfieri</b></li> </ol>

		<p>10. Ivor Lewis esophagectomy after sleeve gastrectomy: the use of gastric conduit is still possible <b>G. Pallabazzer</b></p> <p>11. Esophagectomy for esophageal cancer in an Upper GI unit of the National and Kapodistrian University of Athens during the period 2004-2019 <b>K. Mylonas</b></p>
10:00-10:30	<b>Coffee break</b>	
10:30-12:00	<p><b>Joint session with IGCA</b> Chairs: <b>M. Griffin, W. Schroeder</b></p> <ul style="list-style-type: none"> <li>• Molecular biology in EGJ cancer: Does it affect surgical decision making? <b>I. Gockel</b></li> <li>• Adjunct oncological therapy in junctional adenocarcinoma <b>M. Karamouzis</b></li> <li>• Role of Minimally Invasive Surgery in Siewert III Cancers <b>G. De Manzoni</b></li> <li>• Optimal resection and extend of lymphadenectomy in Siewert II cancers <ul style="list-style-type: none"> <li>➢ IGCA View <b>F. Roviello</b></li> <li>➢ ESDE View <b>R. van Hillegersberg</b></li> </ul> </li> </ul>	<p><b>Facing Achalasia</b> Chairs: <b>D. Schizas, G. Karamanolis</b></p> <ul style="list-style-type: none"> <li>• Manometry in achalasia: Novel tools <b>P. Oustamanolakis</b></li> <li>• Current trends in the management of achalasia <ul style="list-style-type: none"> <li>➢ The optimal surgical approach – HELLER operation <b>A. Alexandrou</b></li> </ul> </li> <li>• The endoscopic approach – POEM <b>G. Mavrogenis</b></li> <li>• Is GERD following achalasia treatment a problem? <b>T. Emmanouil</b></li> <li>• Failed Heller &amp; recurrence of dysphagia <b>I. Karavokyros</b></li> </ul>
12:00-13:00	<p><b>Difficult cases and a step forward?</b> Chairs: <b>A. Charalabopoulos, M. Pera</b></p> <ul style="list-style-type: none"> <li>• Surgical resection of locally advanced T4b tumors <b>W. Schroeder</b></li> <li>• Esophagectomy with unavailable gastric conduit <b>T. Liakakos</b></li> <li>• Surgery for oligometastatic Disease <b>S. Moenig</b></li> </ul>	<p><b>Paraesophageal hernias</b> Chairs: <b>TBA, D. Titcomb</b></p> <ul style="list-style-type: none"> <li>• Work up and surgical indications <b>D. Dellaportas</b></li> <li>• Technical aspects of the optimal repair <b>B. Lorenzi</b></li> <li>• Dealing with the failed repair <b>A. Botha</b></li> </ul>
13:00-14:00	<b>Lunch break</b>	
14:00-15:30	<p><b>Complications post esophagectomy</b> Chairs: <b>A. Botha, M. Nilsson</b></p>	<p><b>Challenging cases</b> Chairs: <b>K. Moorthy, I. Papanikolaou</b></p>



	<ul style="list-style-type: none"> <li>• Preemptive measures to avoid serious leaks <b>M. Cuesta</b></li> <li>• Endoscopic management of anastomotic leaks <b>M. Lindblad</b></li> <li>• Tracheo-esophageal fistula after esophageal resection: scope of the problem and current management <b>D. Van der Peet</b></li> <li>• Conduit related problems <b>M. Pera</b></li> <li>• Management of chylothorax <b>I. Rouvelas</b></li> </ul>	<ul style="list-style-type: none"> <li>• Management of refractory esophageal strictures <b>K. Paraskeva</b></li> <li>• Boerhaave syndrome <b>O. Lyros</b></li> <li>• Hiatal hernia with motility disorders <b>D. Schizas</b></li> <li>• Esophageal foreign bodies <b>I. Stasinou</b></li> <li>• Eosinophilic esophagitis <b>S. Sgouros</b></li> </ul>
15:30-16:00	<b>Coffee break</b>	
16:00-17:30	<p><b>Plenary session</b> Chairs: <b>G. Hanna, G. Zaninotto</b></p> <p><b>16:00-17:00</b> Young investigators meeting – Dragons Den <b>S. Markar</b></p> <p><b>17:00-17:15</b> The UMC Utrecht, ESDE-MIE fellowship program <b>R. Van Hillegersberg</b></p> <p><b>17:15-17:30</b> Meet the Editor of DOTE <b>G. Zaninotto</b></p>	<b>Plenary Session in HALL A</b>
17:30	<p><b>CLOSING REMARKS</b> <b>T. Liakakos, M. Nilsson</b></p>	

